FDA approved the use of a new prefilled syringe Norditropin FlexPro
The U.S. Food and Drug Administration (FDA) approved the use of a new prefilled syringe Norditropin FlexPro made by a pharmaceutical company Novo Nordisk AS. The syringe is designed for the introduction of growth hormone Norditropin (somatropin) in children and adults.
The disposable prefilled syringe Norditropin FlexPro is equipped with a new metering mechanism, and its modern design facilitates the training and use by patients. In addition, it is equipped with a sound indicator of dosing. The use of this prefilled syringe requires to use cartridges. Norditropin FlexPro is available in 3 different doses: 5 mg / 1,5 ml, 10 mg / 1,5 ml and 15 mg / 1,5 ml.
The company Novo Nordisk has produced Norditropin since 1988. In 1999 appeared the first liquid form of the drug Norditropin SimpleXx, and in 2004 – the first pre-filled syringe Norditropin NordiFlex. Development of a new generation prefilled syringe Norditropin FlexPro is the latest achievement of the company in the growth hormone therapy and is based on the Novo Nordisk commitment to maximize the quality of patient care.